following a full submission:
neratinib (Nerlynx®) is accepted for use within NHSScotland
Indication under review: for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
In the relevant subgroup of a phase III study neratinib, given less than one year after adjuvant trastuzumab-based therapy, improved invasive disease-free survival in patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- neratinib (Nerlynx)
- SMC ID:
- SMC2251
- Indication:
Extended adjuvant treatment of adult patients with early-Etage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
- Pharmaceutical company
- Pierre Fabre Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 August 2020